The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Ropeginterferon Alfa-2b for the treatment of low-risk patients with polycythemia vera
Featured:
Tiziano BarbuiDuring the MPN Hub steering committee roundtable discussion we were pleased to invite Dr Tiziano Barbui, Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy to give a talk on his recent abstract presented at ASH 2022 titled ‘Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial.’
Ropeginterferon Alfa-2b for the treatment of low-risk patients with polycythemia vera
He began by introducing the core study design before highlighting results in overall quality of life, splenomegaly and JAK2V617F variable allelic frequency. He concluded with the overall safety findings from the trial.
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?